(Alliance News) - ValiRx PLC said Monday it has so far compiled positive data for the Phase I/IIa trials for VAL201, the company's therapeutic compound for the treatment of prostate cancer.
The clinical stage biotechnology company said the trial for VAL201 is coming to a conclusion, with the trial data collected to date undergoing collation and verification, as well as statistical and scientific analysis.
The results appear to indicate that VAL201 has a clear impact on patients with prostate cancer, and has also demonstrated safety and a high degree of tolerability, up to a dose that is in excess of the predicted dose.
The results are to be submitted to the relevant regulatory authorities as is required, after it has been reviewed and collated by ValiRx's team.
Looking ahead, a late-stage study to determine the overall effectiveness of VAL201 and the most effective therapeutic strategies for its use in disease management is now possible. The late stage study will be designed and set up in parallel to the conclusion of the current early-stage phase I/IIa trial.
"With prostate cancer reported this month in an academic study as being the most common cancer in men in the UK and with an estimated 1.3 million new cases of prostate cancer occurring worldwide last year, it is truly exciting to see VAL201 approaching the conclusion of its Phase I/II first-in-man study," said Chief Executive Officer Satu Vanikka.
"I look forward to regulatory approval of the trial data being speedily reached and the opportunity of potentially demonstrating that VAL201 can address this widespread and often fatal disease in men," Vanikka added.
Shares in ValiRx - which is headquartered in London - remained flat at 0.13 pence on Monday.
By Dayo Laniyan; dayolaniyan@alliancenews.com
Copyright 2019 Alliance News Limited. All Rights Reserved.
ValiRx (VAL)